— Affimed NV (NASDAQ: AFMD) reported Q3 2019 loss of EUR0.17 per share, vs. EUR0.19 reported last year.
— Revenues were EUR2.1 million, vs. EUR0.3 million reported last year.
— Research & development expenses were EUR11.7 million compared to EUR9.8 million last year.
— Cash, cash equivalents and current financial assets totaled EUR76.5 million as of September 30, 2019.
Get access to timely and accurate verbatim transcripts that are published within hours of the event.
Most Popular
AbbVie Q1 2025 adjusted earnings increase on 8% revenue growth; beat estimates
Biopharmaceutical company AbbVie, Inc. (NYSE: ABBV) announced first-quarter 2025 financial results, reporting an increase in revenue and adjusted earnings. The company reported worldwide net revenues of $13.3 billion for the
Colgate-Palmolive (CL) Q1 2025 Earnings: Key financials and quarterly highlights
Colgate-Palmolive Company (NYSE: CL) reported its first quarter 2025 earnings results today. Net sales decreased 3.1% year-over-year to $4.9 billion. Organic sales growth was 1.4%. Net income attributable to Colgate-Palmolive Company rose
Meta Platforms (META) set to report Q1 earnings. Here’s what to expect
After integrating artificial intelligence into its products, Meta Platforms, Inc. (NASDAQ: META) is investing heavily in the metaverse project. Yet, the tech giant has maintained healthy cash flows and consistently
